Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia, Myelodysplastic syndrome (MDS)
Results
Phase 2/3
This trial was looking at non intensive treatment for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS). MDS is called high risk if more than 10% of your is made up of immature cells called blasts.
The trial was supported by Cancer Research UK. It was focusing on those who are over 60 years of age.
There were 2 parts to the AML 16 trial - intensive treatment and non intensive treatment. This summary is about non intensive treatment. The summary about intensive treatment is entered separately on our trials database.
Recruitment start: 4 August 2006
Recruitment end: 30 November 2011
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Alan Burnett
Cancer Research UK
Cardiff University
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/06/026.
Last reviewed: 22 August 2013
CRUK internal database number: 597
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
